TXMD Stock Analysis: Buy, Sell, or Hold?
TXMD - TherapeuticsMD, Inc.
$2.00
0.00 (0.00%)
▲
5d:
-9.91%
30d:
-7.41%
90d:
+22.7%
HOLD
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 18, 2026
Smart Money Accumulation
TXMD is down 6.3% this week, but smart money is accumulating calls. Top strike: $3 2026-06-18 with 142 OI. Call ratio: 100% View Scanner →
Strength: 8.1/10
Get Alerted When TXMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TXMD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TXMD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TXMD is currently trading at $2.00, which is considered oversold relative to its 30-day fair value range of $2.11 to $2.30.
Technical Outlook: Technically, TXMD is in a uptrend. Immediate support is located at $1.90, while resistance sits at $2.40.
Market Sentiment: TXMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.00 (+150.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TXMD is in a uptrend. Immediate support is located at $1.90, while resistance sits at $2.40.
Market Sentiment: TXMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.00 (+150.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.11 -
$2.30
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 150.0% below Wall St target ($5.00)
- CAUTION: Recommendation downgraded due to -9.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.11 -
$2.30
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.41
(20.5%)
Support & Resistance Levels
Support Level
$1.90
Resistance Level
$2.40
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.33
Wall Street Target
$5.00
(+150.0%)
Revenue Growth (YoY)
33.9%
Profit Margin
-18.8%
Share & Embed Analysis
Last updated: April 03, 2026 12:58 AM ET
Data refreshes hourly during market hours. Next update: 1:58 AM
Data refreshes hourly during market hours. Next update: 1:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TXMD showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Tommy G Thompson
BUY
8400 shares
2025-12-23
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 63 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 61 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 56 HOLD |
